FDA Reviews New Data on Anemia Drugs:
New CMS rules
Suite 101
Expert Summary
Due to FDA's review of new data on the dangers of anemia drugs, the Centers for Medicare and Medicaid Services (CMS) established more stringent rules for coverage.
Irina Ostrovsky-Day
Expert Scorecard
Overall Expert Score
Community Reviews
Overall Community Rating:
(0 reviews)
Add your rating:
click to select